Status | Study |
Recruiting |
Study Name: HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Condition: Stevens-Johnson Syndrome Kidney Failure, Chronic Date: 2017-02-06 Interventions: Genetic: HLA-B*5801 test Check whether a participant has HLA-B*5801 allele or not, before administration |
Not yet recruiting |
Study Name: Discerning Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Condition: Prostate Cancer Magnetic Resonance Imaging Date: 2017-02-02 Interventions: Device: MRI/ultrasound transperineal fusion-guided prostate biopsy |
Active, not recruiting |
Study Name: Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae) Condition: Vascular Access Complication Restenosis, Vascular Graft Di Date: 2017-01-19 Interventions: Device: Conventional angioplasty |
Not yet recruiting |
Study Name: Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Condition: Stevens-Johnson Syndrome Toxic Epidermal Necrolyses Date: 2016-11-25 Interventions: Drug: cyclosporin A Other Name |
Active, not recruiting |
Study Name: Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Condition: Graft vs Host Disease Congenital Aniridia Chemical Burns Date: 2016-09-07 Interventions: Device: ARGOS-IO system This study will enroll a minimum of 10 and a maximum of 15 patients. It is antic |
Recruiting |
Study Name: Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Condition: Toxic Epidermal Necrolysis Date: 2016-06-06 Interventions: Drug: Isotretinoin Other: Placebo |
Recruiting |
Study Name: G-CSF in the Treatment of Toxic Epidermal Necrolysis Condition: Stevens - Johnson Syndrome Date: 2016-04-04 Interventions: Drug: recombinant granulocyte - colony stimulating factor |
Recruiting |
Study Name: A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Condition: Stage IV Non-Small Cell Lung Cancer Date: 2016-01-14 Interventions: Drug: Pembrolizumab 200mg Pemb |
Recruiting |
Study Name: Severe Cutaneous Adverse Reactions in Thailand Condition: Steven-Johnson Syndrome Toxic Epidermal Necrolysis Drug Re Date: 2015-10-12 |
Not yet recruiting |
Study Name: Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Condition: Toxic Epidermal Necrolysis Date: 2014-12-15 Interventions: Drug: Clobetasol 0.05% ointment Blinded, daily application to one arm for a period of fourteen (14) days |